Diagnosis and management of pemphigus: Recommendations of an international panel of experts.
Academies and Institutes
/ standards
Administration, Intravenous
Antigens, CD20
/ immunology
Combined Modality Therapy
/ methods
Consensus
Delphi Technique
Dermatology
/ methods
Drug Therapy, Combination
/ methods
Europe
Glucocorticoids
/ administration & dosage
Humans
Immunologic Factors
/ administration & dosage
Pemphigus
/ diagnosis
Plasmapheresis
Practice Guidelines as Topic
Rituximab
/ administration & dosage
Severity of Illness Index
CD20 inhibitor
consensus
guidelines
pemphigus foliaceus
pemphigus vulgaris
treatment
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
23
03
2017
revised:
18
01
2018
accepted:
03
02
2018
pubmed:
14
2
2018
medline:
12
9
2020
entrez:
14
2
2018
Statut:
ppublish
Résumé
Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management. We now present results from a subsequent Delphi consensus to broaden the generalizability of the recommendations. A preliminary survey, based on the European Dermatology Forum and the European Academy of Dermatology and Venereology guidelines, was sent to a panel of international experts to determine the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in March 2016 during the annual American Academy of Dermatology conference. Following the meeting, a second survey was sent to more experts to achieve greater international consensus. The 39 experts participated in the first round of the Delphi survey, and 54 experts from 21 countries completed the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in Delphi II on the basis of Delphi results and meeting discussion. Each recommendation represents the majority opinion and therefore may not reflect all possible treatment options available. We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first-line therapy option for moderate-to-severe pemphigus.
Sections du résumé
BACKGROUND
BACKGROUND
Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management.
OBJECTIVE
OBJECTIVE
We now present results from a subsequent Delphi consensus to broaden the generalizability of the recommendations.
METHODS
METHODS
A preliminary survey, based on the European Dermatology Forum and the European Academy of Dermatology and Venereology guidelines, was sent to a panel of international experts to determine the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in March 2016 during the annual American Academy of Dermatology conference. Following the meeting, a second survey was sent to more experts to achieve greater international consensus.
RESULTS
RESULTS
The 39 experts participated in the first round of the Delphi survey, and 54 experts from 21 countries completed the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in Delphi II on the basis of Delphi results and meeting discussion.
LIMITATIONS
CONCLUSIONS
Each recommendation represents the majority opinion and therefore may not reflect all possible treatment options available.
CONCLUSIONS
CONCLUSIONS
We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first-line therapy option for moderate-to-severe pemphigus.
Identifiants
pubmed: 29438767
pii: S0190-9622(18)30207-X
doi: 10.1016/j.jaad.2018.02.021
pmc: PMC7313440
mid: NIHMS1597607
pii:
doi:
Substances chimiques
Antigens, CD20
0
Glucocorticoids
0
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-585.e1Subventions
Organisme : NIAMS NIH HHS
ID : P30 AR069589
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR032599
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007465
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
J Am Acad Dermatol. 2012 Mar;66(3):479-85
pubmed: 22056920
Br J Dermatol. 2016 Jul;175(1):142-9
pubmed: 26800395
J Dermatol. 2014 Jun;41(6):471-86
pubmed: 24909210
J Am Acad Dermatol. 2003 Dec;49(6):1059-62
pubmed: 14639384
Immunol Allergy Clin North Am. 2012 May;32(2):233-43, v-vi
pubmed: 22560136
Ann Dermatol Venereol. 2011 Mar;138(3):252-8
pubmed: 21397155
J Dtsch Dermatol Ges. 2015 Aug;13(8):833-44
pubmed: 26213827
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):405-14
pubmed: 25338479
Lancet. 2017 May 20;389(10083):2031-2040
pubmed: 28342637
J Dermatol. 2014 Nov;41(11):969-73
pubmed: 25346300
Br J Dermatol. 2003 Nov;149(5):926-37
pubmed: 14632796